These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 29054920)
1. CSF β-amyloid and white matter damage: a new perspective on Alzheimer's disease. Pietroboni AM; Scarioni M; Carandini T; Basilico P; Cadioli M; Giulietti G; Arighi A; Caprioli M; Serra L; Sina C; Fenoglio C; Ghezzi L; Fumagalli GG; De Riz MA; Calvi A; Triulzi F; Bozzali M; Scarpini E; Galimberti D J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):352-357. PubMed ID: 29054920 [TBL] [Abstract][Full Text] [Related]
2. Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension. Al-Janabi OM; Brown CA; Bahrani AA; Abner EL; Barber JM; Gold BT; Goldstein LB; Murphy RR; Nelson PT; Johnson NF; Shaw LM; Smith CD; Trojanowski JQ; Wilcock DM; Jicha GA J Alzheimers Dis; 2018; 66(3):1095-1104. PubMed ID: 30400099 [TBL] [Abstract][Full Text] [Related]
3. Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. Wang Q; Wang Y; Liu J; Sutphen CL; Cruchaga C; Blazey T; Gordon BA; Su Y; Chen C; Shimony JS; Ances BM; Cairns NJ; Fagan AM; Morris JC; Benzinger TLS Neuroimage Clin; 2019; 22():101767. PubMed ID: 30901713 [TBL] [Abstract][Full Text] [Related]
4. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470 [TBL] [Abstract][Full Text] [Related]
5. Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes. Pietroboni AM; Carandini T; Colombi A; Mercurio M; Ghezzi L; Giulietti G; Scarioni M; Arighi A; Fenoglio C; De Riz MA; Fumagalli GG; Basilico P; Serpente M; Bozzali M; Scarpini E; Galimberti D; Marotta G Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):280-287. PubMed ID: 30343433 [TBL] [Abstract][Full Text] [Related]
6. White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β. Freeze WM; Jacobs HI; Gronenschild EH; Jansen JF; Burgmans S; Aalten P; Clerx L; Vos SJ; van Buchem MA; Barkhof F; van der Flier WM; Verbeek MM; Rikkert MO; Backes WH; Verhey FR; J Alzheimers Dis; 2017; 55(1):333-342. PubMed ID: 27662299 [TBL] [Abstract][Full Text] [Related]
7. Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage. Pietroboni AM; Colombi A; Carandini T; Sacchi L; Fenoglio C; Marotta G; Arighi A; De Riz MA; Fumagalli GG; Castellani M; Bozzali M; Scarpini E; Galimberti D Alzheimers Res Ther; 2022 Feb; 14(1):33. PubMed ID: 35151361 [TBL] [Abstract][Full Text] [Related]
8. Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer's disease with and without cerebrovascular disease. Ji F; Pasternak O; Liu S; Loke YM; Choo BL; Hilal S; Xu X; Ikram MK; Venketasubramanian N; Chen CL; Zhou J Alzheimers Res Ther; 2017 Aug; 9(1):63. PubMed ID: 28818116 [TBL] [Abstract][Full Text] [Related]
9. CSF β-amyloid predicts prognosis in patients with multiple sclerosis. Pietroboni AM; Caprioli M; Carandini T; Scarioni M; Ghezzi L; Arighi A; Cioffi S; Cinnante C; Fenoglio C; Oldoni E; De Riz MA; Basilico P; Fumagalli GG; Colombi A; Giulietti G; Serra L; Triulzi F; Bozzali M; Scarpini E; Galimberti D Mult Scler; 2019 Aug; 25(9):1223-1231. PubMed ID: 30084711 [TBL] [Abstract][Full Text] [Related]
10. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314 [TBL] [Abstract][Full Text] [Related]
11. White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. Gold BT; Zhu Z; Brown CA; Andersen AH; LaDu MJ; Tai L; Jicha GA; Kryscio RJ; Estus S; Nelson PT; Scheff SW; Abner E; Schmitt FA; Van Eldik LJ; Smith CD Neurobiol Aging; 2014 Oct; 35(10):2263-71. PubMed ID: 24866404 [TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
14. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease. Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038 [TBL] [Abstract][Full Text] [Related]
15. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. van Loenhoud AC; van der Flier WM; Wink AM; Dicks E; Groot C; Twisk J; Barkhof F; Scheltens P; Ossenkoppele R; Neurology; 2019 Jul; 93(4):e334-e346. PubMed ID: 31266904 [TBL] [Abstract][Full Text] [Related]
19. Associations of Alzheimer's Disease Pathology and Small Vessel Disease With Cerebral White Matter Degeneration: A Tract-Based MR Diffusion Imaging Study. Li K; Wang S; Luo X; Zeng Q; Liu X; Hong L; Li J; Hong H; Xu X; Zhang Y; Jiaerken Y; Zhang R; Xie L; Xu S; Zhang X; Chen Y; Liu Z; Zhang M; Huang P J Magn Reson Imaging; 2024 Jul; 60(1):268-278. PubMed ID: 37737474 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]